Spruce Street Capital LP Acquires Shares of 1,088,731 Enanta Pharmaceuticals, Inc. $ENTA

Spruce Street Capital LP bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,088,731 shares of the biotechnology company’s stock, valued at approximately $15,873,698,000. Enanta Pharmaceuticals makes up 3.1% of Spruce Street Capital LP’s investment portfolio, making the stock its 11th largest position. Spruce Street Capital LP owned approximately 3.74% of Enanta Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Meeder Asset Management Inc. acquired a new position in Enanta Pharmaceuticals during the 4th quarter worth $32,000. Seven Fleet Capital Management LP bought a new stake in shares of Enanta Pharmaceuticals during the fourth quarter worth $36,000. Strs Ohio acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 333.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 2,758 shares during the last quarter. Finally, Clearstead Trust LLC acquired a new stake in Enanta Pharmaceuticals in the second quarter worth about $74,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA opened at $14.10 on Tuesday. The stock has a 50 day simple moving average of $13.48 and a 200 day simple moving average of $13.46. Enanta Pharmaceuticals, Inc. has a 52-week low of $7.05 and a 52-week high of $17.15. The firm has a market capitalization of $410.59 million, a PE ratio of -5.85 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.84%. The company had revenue of $14.36 million during the quarter, compared to analyst estimates of $16.76 million. Equities research analysts predict that Enanta Pharmaceuticals, Inc. will post -2.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ENTA shares. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $19.50.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.